Atlas Trials

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06055075 · COMPLETED

Trial details

NCT number
NCT06055075
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2023-12-12
Primary completion
2025-07-08
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.